Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
作者信息
Park Sang Hyoung, Ye Byong Duk, Yang Suk-Kyun
机构信息
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
出版信息
Gut Liver. 2022 Jan 15;16(1):138-140. doi: 10.5009/gnl210246.
Abstract
摘要
相似文献
1
Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
Gut Liver. 2022 Jan 15;16(1):138-140. doi: 10.5009/gnl210246.
2
Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
World J Gastroenterol. 2015 Mar 21;21(11):3282-90. doi: 10.3748/wjg.v21.i11.3282.
3
Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
Indian J Gastroenterol. 2020 Dec;39(6):565-575. doi: 10.1007/s12664-020-01092-1. Epub 2020 Oct 27.
4
Submandibular Sialoadenitis in an Infant Exposed to Adalimumab and Infliximab in Utero.
J Crohns Colitis. 2017 Oct 1;11(10):1284-1285. doi: 10.1093/ecco-jcc/jjx045.
5
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
Aliment Pharmacol Ther. 2020 May;51(9):852-860. doi: 10.1111/apt.15680. Epub 2020 Mar 22.
6
Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2023 Oct;21(11):2978-2980.e2. doi: 10.1016/j.cgh.2022.10.037. Epub 2022 Nov 11.
7
An update on anti-TNF agents in ulcerative colitis.
Gastroenterol Clin North Am. 2014 Sep;43(3):479-94. doi: 10.1016/j.gtc.2014.05.006.
8
Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy.
Medicine (Baltimore). 2017 Aug;96(32):e7800. doi: 10.1097/MD.0000000000007800.
9
Small-Fiber Neuropathy in a Pediatric Patient Following Anti-Tumor Necrosis Factor-α Therapy for Ulcerative Colitis.
J Pediatr Gastroenterol Nutr. 2018 Jun;66(6):e159-e161. doi: 10.1097/MPG.0000000000001992.
10
[Golimumab Therapy in Ulcerative Colitis].
Korean J Gastroenterol. 2016 Feb;67(2):64-73. doi: 10.4166/kjg.2016.67.2.64.
本文引用的文献
1
Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study.
Intest Res. 2021 Oct;19(4):408-418. doi: 10.5217/ir.2020.00025. Epub 2020 Nov 20.
2
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study.
Intest Res. 2021 Oct;19(4):419-429. doi: 10.5217/ir.2020.00033. Epub 2020 Nov 10.
3
Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018.
Intest Res. 2021 Apr;19(2):186-193. doi: 10.5217/ir.2020.00028. Epub 2020 Aug 18.
4
Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis.
Gut Liver. 2021 Mar 15;15(2):232-242. doi: 10.5009/gnl19433.
5
Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns?
J Anus Rectum Colon. 2020 Jan 30;4(1):1-13. doi: 10.23922/jarc.2019-003. eCollection 2020.
6
Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea.
Gut. 2020 Aug;69(8):1432-1440. doi: 10.1136/gutjnl-2019-319699. Epub 2019 Dec 10.
7
Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: A Hospital-Based Cohort Study.
Gut Liver. 2020 May 15;14(3):347-356. doi: 10.5009/gnl19137.
8
A 30-year Trend Analysis in the Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015.
J Crohns Colitis. 2019 Oct 28;13(11):1410-1417. doi: 10.1093/ecco-jcc/jjz081.
9
A new opportunity for innovative inflammatory bowel disease research: the moderate-to-severe ulcerative colitis in Korea (MOSAIK) cohort study.
Intest Res. 2019 Jan;17(1):1-5. doi: 10.5217/ir.2019.00005. Epub 2019 Jan 25.
10
Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study.
Intest Res. 2019 Jan;17(1):54-62. doi: 10.5217/ir.2018.00096. Epub 2018 Nov 20.
Zotero 插件